Advancements in recanalization therapies have rendered reperfusion injury an important challenge for stroke management. It is essential to work toward effective therapeutics that protect the ischemic brain from reperfusion injury. Here, we report a new concept of neuroprognostic agents, which combine molecular diagnostic imaging and targeted neuroprotection for treatment of reperfusion injury after stroke. These neuroprognostic agents are inflammation-targeted gadolinium compounds conjugated with nonsteroidal anti-inflammatory drugs (NSAIDs). Our results demonstrated that gadolinium-based MRI contrast agents conjugated with NSAIDs suppressed the increase in cyclooxygenase-2 (COX-2) levels, ameliorated glial activation, and neuron damage that are phenotypic for stroke by mitigating neuroinflammation, which prevented reperfusion injury. In addition, this study showed that the neuroprognostic agents are promising T₁ molecular MRI contrast agents for detecting precise reperfusion injury locations at the molecular level. Our results build on this new concept of neuroprognostics as a novel management strategy for ischemia-reperfusion injury, combining neuroprotection and molecular diagnostics.

中文翻译：

---

基于的神经预后磁共振成像剂可抑制COX-2，以预防中风后再灌注损伤。

再通疗法的进步使再灌注损伤成为中风管理的重要挑战。必须采取有效的疗法来保护缺血性脑免受再灌注损伤。在这里，我们报告了神经预后药的新概念，它将分子诊断成像和靶向神经保护相结合，用于治疗中风后的再灌注损伤。这些神经预后剂是与非甾体抗炎药（NSAID）缀合的针对炎症的g化合物。我们的研究结果表明，与NSAID偶联的基于lin的MRI造影剂可通过减轻神经炎症来抑制环氧合酶2（COX-2）水平的增加，神经胶质激活和中风表型的神经元损伤，从而防止再灌注损伤。此外，T ₁分子MRI造影剂，用于在分子水平检测精确的再灌注损伤部位。我们的研究结果基于神经预后的新概念，将其作为一种新的缺血再灌注损伤管理策略，将神经保护和分子诊断相结合。